A 50-year-old male patient with agitated depression and hyperlipemia received oral amoxicillin and clavulanate potassium 0.5 g once daily and 2 lopinavir and ritonavir tablets twice daily for novel coronavirus infection, based on previous drugs including quetiapine, clonazepam, and atorvastatin calcium. After 3 days, lopinavir and ritonavir was changed to oral arbidol 200 mg, thrice daily due to suspicious drug interaction. After taking arbidol for 3 days, the patient developed red papules on the whole body. Considering that it might be related to amoxicillin and clavulanate potassium, the drug was stopped and loratadine was given. But the rashes were aggravated. Considering that the drug eruption was caused by arbidol, arbidol was discontinued and the rashes subsided in a large area the next day. Then vitamin C injection, calcium gluconate injection, and ribavirin were added. After 5 days, the rashes subsided completely. After 17 days, the patient recovered from pneumonia.

A 55-year-old male patient with hepatic complex alveolar echinococcosis, who had a history of gout for more than 4 years, developed swelling and high skin temperature of feet when he waited for the result of remote consultation and prepared for optional right hemihepatectomy in the hospital. Laboratory tests showed that uric acid was 530 μmol/L and rheumatic factor was negative. Acute gout attack was considered. He was treated with oral colchicine 0.5 mg thrice daily. About 10 hours after the first administration, the patient developed urinary incontinence. According to the consultation results, it was considered that the urinary incontinence might be related to colchicine. Colchicine was stopped immediately. The symptoms of urinary incontinence disappeared 24 hours after drug withdrawal. The symptoms of urinary incontinence recurred after the patient took the drug again by himself. Urinary incontinence did not recur after the colchicine withdrawal again.

A 50-year-old male patient with agitated depression and hyperlipemia received oral amoxicillin and clavulanate potassium 0.5 g once daily and 2 lopinavir and ritonavir tablets twice daily for novel coronavirus infection, based on previous drugs including quetiapine, clonazepam, and atorvastatin calcium. After 3 days, lopinavir and ritonavir was changed to oral arbidol 200 mg, thrice daily due to suspicious drug interaction. After taking arbidol for 3 days, the patient developed red papules on the whole body. Considering that it might be related to amoxicillin and clavulanate potassium, the drug was stopped and loratadine was given. But the rashes were aggravated. Considering that the drug eruption was caused by arbidol, arbidol was discontinued and the rashes subsided in a large area the next day. Then vitamin C injection, calcium gluconate injection, and ribavirin were added. After 5 days, the rashes subsided completely. After 17 days, the patient recovered from pneumonia.

A 55-year-old male patient with hepatic complex alveolar echinococcosis, who had a history of gout for more than 4 years, developed swelling and high skin temperature of feet when he waited for the result of remote consultation and prepared for optional right hemihepatectomy in the hospital. Laboratory tests showed that uric acid was 530 μmol/L and rheumatic factor was negative. Acute gout attack was considered. He was treated with oral colchicine 0.5 mg thrice daily. About 10 hours after the first administration, the patient developed urinary incontinence. According to the consultation results, it was considered that the urinary incontinence might be related to colchicine. Colchicine was stopped immediately. The symptoms of urinary incontinence disappeared 24 hours after drug withdrawal. The symptoms of urinary incontinence recurred after the patient took the drug again by himself. Urinary incontinence did not recur after the colchicine withdrawal again.

To investigate the effect of crocin on the progression and generalized seizure of temporal lobe epilepsy in mice.Hippocampus rapid kindling model was established in C57BL/6J mice. The effects of crocin on seizure stage, afterdischarge duration (ADD), number of stimulation in each stage and final state, the incidence of generalized seizure (GS), average seizure stage and ADD were observed.Crocin (20 mg/kg) significantly retarded behavioral seizure stages (<0.05) and shortened cumulative ADD (<0.01) during hippocampus rapid kindling acquisition in mice compared with vehicle group. Meanwhile, number of stimulations in stage 1-2 was significantly increased (<0.05) and the incidence of fully kindled animals was significantly decreased (<0.01). However, 10 or 50 mg/kg crocin showed no significant effect on the above indexes (all>0.05). Crocin (100 or 200 mg/kg) significantly decreased the incidence of GS (all<0.01) and reduced average seizure stages (all<0.01) in fully-kindled mice compared with vehicle group; Fifty mg/kg crocin only reduced average seizure stages (<0.05).Low-dose crocin can retard the progression in hippocampus rapid kindling acquisition in mice, while high-dose crocin relieves the GS in fully-kindled mice, which suggests that crocin may be a potential anti-epileptic compound.
Animals ; Anticonvulsants ; pharmacology ; Carotenoids ; pharmacology ; therapeutic use ; Dose-Response Relationship, Drug ; Electric Stimulation ; Epilepsy, Temporal Lobe ; chemically induced ; drug therapy ; Hippocampus ; drug effects ; physiopathology ; Kindling, Neurologic ; drug effects ; physiology ; Mice ; Mice, Inbred C57BL ; Seizures ; classification ; drug therapy

Objective To investigate clinical effect of sparfloxacin on the treatment of ureaplasma urealyticum prostatitis.Methods 96 cases with ureaplasma urealyticum prostatitis, which admitted in our hospital, were selected as the research object and divided into observation group ( n =48 cases) and control group ( n=48 cases) randomly.The control group was given the ofloxacin for treatment and the observation group was given the sparfloxacin for treatment.The clinical effect of the two groups after treatment was analyzed.Results The total effective rate of the observation group (97.92%) was significantly higher than that of the control group (72.92%) (P<0.05).After treatment, the total incidence of adverse reactions of the observation group(8.33%) compared with that of the control group (10.42%), had no significant difference(P>0.05).Conclusion Patients with ureaplasma urealyticum prostatitis, the treatment effect of sparfloxacin is significant, with lower adverse reactions rate and the security is higher, which is recognized in the medical community, can be worthy of popularization and application in clinic.